Home > Insider Trading > Filing (0000899243-20-008490)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1672619	Imara Inc.	IMRA	Pharmaceutical Preparations (2834)	811523849

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1734389	Mark Chin	20 Berkeley Square Mayfair, London X0 W1J 6EQ		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-03-16	1,367,058	$0.00	1,367,058	No	4	C	Indirect	By entities affiliated with Arix Bioscience plc
Common Stock	Acquisiton	2020-03-16	187,500	$16.00	1,554,558	No	4	P	Indirect	By entities affiliated with Arix Bioscience plc

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By entities affiliated with Arix Bioscience plc
No	4	P	Indirect	By entities affiliated with Arix Bioscience plc

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2020-03-16	8,611,110	$0.00	1,367,058	$0.00
Common Stock	Stock Option (right to buy)	Acquisiton	2020-03-16	15,457	$0.00	15,457	$16.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
15,457		2030-03-15	No	4	A	Direct

Footnotes

On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
The reporting person is a member of the Investment Committee of Arix and shares voting and dispositive power over the shares held by Arix. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose.
The option vests in three equal installments on March 16, 2021, 2022 and 2023.